carbamates has been researched along with dabrafenib in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Belum, VR; Busam, KJ; Carvajal, RD; Chapman, PB; Dranitsaris, G; Jaimes, N; Lacouture, ME; Marghoob, AA; Pulitzer, MP; Rosen, AC | 1 |
| Dummer, R; Galliker, NA; Goldinger, SM; Kamarashev, J; Murer, C | 1 |
| Adelmann, CH; Bansal, V; Ching, G; Du, L; Lee, W; Liang, R; Pence, LJ; Saporito, RC; Tsai, KY | 1 |
| Aractingi, S; Avril, MF; Boitier, F; Boulinguez, S; Chanal, J; Deilhes, F; Dupin, N; Guégan, S; Kramkimel, N; Meyer, N; Regnier-Rosencher, E; Vanhaecke, C | 1 |
| Avan, A; Bahrami, A; Ferns, GA; Hassanian, SM; Hesari, A; Khazaei, M | 1 |
| Daud, A; Tsai, K | 1 |
| Alaibac, M; Chiarion Sileni, V; Frigo, AC; Russo, I; Zorzetto, L | 1 |
| Dippel, E; Gutzmer, R; Herbst, R; Kreuter, A; Mohr, P; Okoye, S; Pföhler, C; Satzger, I; Schadendorf, D; Schaper-Gerhardt, K; Sucker, A; Terheyden, P; Ugurel, S; Ulrich, J; Utikal, JS | 1 |
| Benzaquen, M; Berbis, P; Bonnet, N; Brue, A; Default, A; Delaporte, E; Koeppel, MC | 1 |
| Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Calapre, L; Gray, ES; McEvoy, A; Meniawy, TM; Millward, M; Pereira, M; Warburton, L; Ziman, M | 1 |
| Enzler, F; Feichtner, A; Fleischmann, J; Hartl, M; Huber, RG; Mayrhofer, JE; Ogris, E; Raffeiner, A; Röck, R; Schneider, R; Stefan, E; Torres-Quesada, O; Troppmair, J; Tschaikner, P | 1 |
| Baric, L; Cantagrel, A; Di Palma, M; Ederhy, S; Paques, M; Perlemuter, G; Sibaud, V | 1 |
| Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH | 1 |
| Kono, M; Noto, M; Sato, T; Yamada, M | 1 |
3 review(s) available for carbamates and dabrafenib
| Article | Year |
|---|---|
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cinnamates; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Oximes; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2018 |
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Fever; Humans; Imidazoles; Indoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Sulfonamides; Vemurafenib | 2017 |
[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Drug Combinations; Humans; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Vemurafenib | 2021 |
13 other study(ies) available for carbamates and dabrafenib
| Article | Year |
|---|---|
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Female; Humans; Imidazoles; Indoles; Male; Middle Aged; Neoplasms; Oximes; Protein Kinase Inhibitors; Skin Diseases; Sulfonamides; Vemurafenib | 2015 |
Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Male; Melanoma; Mitogen-Activated Protein Kinases; Oximes; Panniculitis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides | 2015 |
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
Topics: Apoptosis; Carbamates; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Enzyme Activation; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2016 |
BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Topics: Adult; Antineoplastic Agents; Carbamates; Drug Substitution; Humans; Imidazoles; Indoles; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Oximes; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult | 2017 |
A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Melanoma; Melanoma, Cutaneous Malignant; Mutation; Oximes; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Skin Neoplasms; Sulfonamides; Vemurafenib | 2017 |
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carbamates; Female; Humans; Imidazoles; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Oximes; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult | 2018 |
Desensitization protocol for angio-oedema induced by encorafenib in a patient with metastatic melanoma.
Topics: Carbamates; Edema; Humans; Imidazoles; Melanoma; Oximes; Sulfonamides | 2019 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma.
Topics: Adult; Aged; Carbamates; Circulating Tumor DNA; Disease Progression; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2020 |
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
Topics: A549 Cells; Carbamates; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Lung Neoplasms; Mutation; Oximes; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2020 |
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Cardiovascular Diseases; Colonic Neoplasms; Cross-Sectional Studies; Female; Heart Failure; Humans; Hypertension; Imidazoles; Lung Neoplasms; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Registries; Regression Analysis; Skin Neoplasms; Sulfonamides; Vemurafenib; Venous Thromboembolism; Young Adult | 2021 |
Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Lactate Dehydrogenases; Melanoma; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides | 2022 |